MTP to develop EnVivo's lead candidate in Asia
This article was originally published in Scrip
Mitsubishi Tanabe Pharma (MTP) has licensed in rights for Japan and other Asian markets to EnVivo Pharmaceuticals' lead product candidate EVP-6124. The oral alpha-7 nicotinic acetylcholine receptor agonist is being developed for cognitive impairment associated with Alzheimer's disease and schizophrenia.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.